Original research

Functional analysis of TLK2 variants and their proximal interactomes implicates impaired kinase activity and chromatin maintenance defects in their pathogenesis

Lisa Pavinato 1,2, Marina Villamor-Payà 3, Maria Sanchiz-Calvo 3, Cristina Andreoli 4, Marina Gay 3, Marta Vilaseca 3, Gianluca Arauz-Garofalo 3, Andrea Ciolfi 5, Alessandro Bruselles 6, Tommaso Pippucci 7, Valentina Prota 4, Diana Carli 8, Elisa Giorgio 1,9 Francesca Clementina Radio 5, Vincenzo Antonia 10, Mario Giuffrè 10, Kara Ranguin 10,11 Cindy Colson 11, Silvia De Rubeis 12,13,14,15 Paola Dimartino 16, Joseph D Buxbaum 12,13,14,15,17,18 Giovanni Battista Ferrero 8, Marco Tartaglia 5, Simone Martinelli 19, Travis H Stracker 3,20 Alfredo Brusco 1,21

ABSTRACT

Introduction The Tousled-like kinases 1 and 2 (TLK1 and TLK2) are involved in many fundamental processes, including DNA replication, cell cycle checkpoint recovery and chromatin remodelling. Mutations in TLK2 were recently associated with "Mental Retardation Autosomal Dominant 57" (MRD57, MIM# 618050), a neurodevelopmental disorder characterised by a highly variable phenotype, including mild-to-moderate intellectual disability, behavioural abnormalities, facial dysmorphisms, microcephaly, epilepsy and skeletal anomalies.

Methods We re-evaluate whole exome sequencing and array-CGH data from a large cohort of patients affected by neurodevelopmental disorders. Using spatial proteomics (BioID) and single-cell gel electrophoresis, we investigated the proximity interaction landscape of TLK2 and analysed the effects of p.(Asp551Gly) and a previously reported missense variant (c.1850C>T) in TLK2 and analysed the effects of p.(Asp551Gly) and TLK2 function and provides new insights into its role in neurodevelopmental disorders.

Results We identified three new unrelated MRD57 families. Two were sporadic and caused by a missense change (c.1652A>G; p.(Asp551Gly)) or a 39 kb deletion encompassing TLK2, and one was familial with three affected siblings who inherited a nonsense change (c.1423G>T; p.(Glu475Ter)). The clinical phenotypes were consistent with those of previously reported cases. The tested mutations strongly impaired TLK2 kinase activity. Proximal interactions between TLK2 and other factors implicated in neurodevelopmental disorders, including CHD7, CHD8, BRD4 and NACC1, were identified. Finally, we demonstrated a more relaxed chromatin state in lymphoblastoid cells harbouring the p.(Asp551Gly) variant compared with control cells, conferring susceptibility to DNA damage.

Conclusion Our study identified novel TLK2 pathogenic variants, confirming and further expanding the MRD57-related phenotype. The molecular characterisation of missense variants increases our knowledge about TLK2 function and provides new insights into its role in neurodevelopmental disorders.

INTRODUCTION

The Tousled-like kinases 1 and 2 (TLK1 and TLK2) are serine-threonine kinases involved in DNA replication and repair, transcription, cell cycle checkpoint recovery, chromatin maintenance and genomic stability.1–3 Both kinases target the ASF1A and ASF1B histone H3/H4 chaperones and are regulated by DNA damage responsive checkpoint signalling.4 Depletion of Tlk1 and Tlk2 in mice indicated that they are largely redundant, with the exception of an essential role for Tlk2 in placental development.5 Null Tlk2 mice, generated with a conditional allele to bypass the placental defect, showed no gross developmental defects except for a slight growth delay compared with controls, suggesting that Tlk1 can compensate for loss of Tlk2 function after embryonic development. Further work in human cancer cells supports extensive redundancy at the cellular level. Co-depletion of TLK1 and TLK2, however, causes replication stress, DNA damage and altered chromatin maintenance, particularly affecting telomeres and other repetitive genome elements, while mild effects were observed with depletion of either protein.6

Mutations in TLK2 were associated with Mental Retardation Autosomal Dominant 57 (MRD57, MIM# 618050) by Reijnders et al.,7 who described 40 cases from 38 unrelated families. MRD57 is clinically characterised by autism spectrum disorder (ASD), intellectual disability (ID), behavioural problems, growth delay and facial dysmorphism, including blepharophimosis, telecanthus, prominent nasal bridge, broad nasal tip, thin vermilion of the upper lip and upslanting palpebral fissures. Other features shared by a subset of cases are...
gastrointestinal problems, seizures, skeletal malformations and ocular problems.

In the majority of reported cases, the disease is likely due to TLK2 haploinsufficiency, as most of cases are heterozygous for loss-of-function (LoF) alleles, which is in line with the strong constraint against LoF variants in the gene (pLI=1, GnomAD database). Reported missense variants cluster mainly in the C-terminal protein kinase domain (PKD), the core of TLK2 function. Four TLK2 variants localised in this region have previously been analysed, showing a strong reduction of kinase activity on ASF1A in vitro. TLK2 activation requires dimerisation through an N-terminal coiled coil motif, suggesting that inactive mutants could have a dominant negative effect. Thus, based on the available data, the predominant pathogenic mechanism of TLK2 mutations appears to be a reduction in its overall activity. Of note, recent work suggested a possible autosomal recessive phenotype in a proband affected by severe neurodevelopmental disease with a homozygous missense variant (c.163A>G; p.(Lys55Glu)). This variant is localised outside the TLK2 PKD and coiled-coil motifs, and may be hypomorphic, since the carrier parents are not affected.

During the screening of a large survey of patients with ID by array-CGH and whole exome sequencing (WES), we identified three new cases with TLK2-mutations. Two subjects were heterozygous for a de novo 39 kb deletion encompassing TLK2, and a de novo c.1652A>G; p.(Asp551Gly) missense change. The third case was familial, with a nonsense variant (c.1423G>T; p.Glu475Ter) occurring in three affected siblings and their affected mother. Here, we report their clinical description, confirming and expanding the disease phenotype. We also provide data documenting an altered chromatin state in patient-derived fibroblasts and lymphoblastoid cells (LCLs), consistent with a defect in the regulation of histone chaperones. Finally, we characterised the activity and proximal interactomes of the p.(Asp551Gly) variant, as well as another missense variant (p.(Ser617Leu)), reported in a several published studies. The p.(Asp551Gly) variant, as well as another missense variant we characterised the activity and proximal interactomes of derived fibroblasts and lymphoblastoid cells (LCLs), consistent with the clinical work from Reijnders et al., we specified variants also in NM_006852.6 in online supplemental table S2.

**In silico prediction of missense variants impact and splicing analysis**

Variants were analysed with the VarSome tool as a starting point for further analysis. This allowed evaluation of at least 15 in silico predictors simultaneously. Variants frequencies were evaluated using Genome Aggregation Database (GnomAD) Browser V2.1.1. Impaired splicing was predicted using Human Splicing Finder V3.1 and experimentally verified as described in online supplemental materials and methods.

**Cell cultures**

Peripheral blood mononuclear cells were isolated from whole blood using Histopaque-1077 (Sigma-Aldrich) and subsequently immortalised with Epstein-Barr virus and cultured in RPMI medium (Gibco, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) (Gibco), 1% penicillin-streptomycin and 1% L-glutamine. Primary fibroblasts were isolated from human skin biopsies after overnight incubation in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich) supplemented with 10% FBS and 160µg/mL collagenase. Fibroblasts were maintained in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin and 1mM sodium pyruvate (Thermo Fisher Scientific) at 37°C, 5% CO2. AD-293 cells (Strategene) were grown in DMEM supplemented with 10% FBS (Sigma-Aldrich), 50 µM penicillin and 50 µg/mL streptomycin (Thermo Fisher Scientific) at 37°C in a 5% CO2 incubator.

**RNA isolation and quantitative real-time PCR**

Total RNA was extracted from fibroblasts and LCLs using the Direct-Zol RNA MiniPrep system (Zymo Research, Irvine, California, USA) and cDNA was generated using the M-MLV Reverse Transcriptase kit (Invitrogen, Thermo Fisher Scientific). The expression level of TLK2 was measured using the Universal Probe Library system (Roche Diagnostics, Risch-Rotkreuz, Switzerland) with primers and probe in online supplemental table S1 and HMB8 and GAPDH as reference gene (assays numbers Hs00609297_m1 and Hs00266705_g1; Applied Biosystems, Thermo Fisher Scientific). Assays were carried out in triplicate on an ABI 7500 real-time PCR instrument using the ABI 2X TaqMan Universal PCR Master Mix II, according to the manufacturer’s protocol (Thermo Fisher Scientific). For each experiment, biological triplicates with at least two technical replicates were performed. Data were analysed with Prism-GraphPad Software performing unpaired t-test with Welch’s correction. P values are indicated as follows: ns=p>0.05; *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001.

**Single-cell gel electrophoresis**

Samples were prepared according to the alkaline single-cell gel electrophoresis (SCGE) assay method, as previously described and are briefly summarised in online supplemental material and methods, together with experimental details.

**Site directed mutagenesis and in vitro kinase assays from cell lysates**

In vitro kinase assays were performed as previously described with minor modifications. Full methods are provided in the online supplemental material and methods and primers in online supplemental table S3.
Western blot analysis
For affinity purification (AP), 40 μg of input protein and 20 μL of Strep-AP elution, with 6X SDS (0.2% bromophenol blue and β-mercaptoethanol), were separated by SDS-PAGE and transferred to nitrocellulose membranes (0.2 or 0.45 μm pore, Amer sham Protran; Sigma-Aldrich). For detection of streptavidin, polyvinylidene fluoride membranes (0.45 μm pore, Immobilon-P, Merck) were used. Membranes were blocked and antibodies prepared in 5% non-fat milk in PBS-Tween20 (PBS-T), with the exception of CHD7 and CHD8, where 5% bovine serum albumin in PBS-T was used. Primary antibodies were detected with the appropriate secondary antibodies conjugated to horseradish peroxidase (HRP) (online supplemental table S4) and visualised by ECL-Plus (GE Healthcare).

Proximity-dependent biotin identification mass spectrometry (BioID-MS)
BioID-MS and BioID-westerns were performed essentially as described in the study by Silva et al19 with some modifications. Full methods are provided in the online supplemental materials and methods and data are available in the PRIDE database with accession number PXD019450.

RESULTS
Identification of novel MRD57 patients
The identification of TLK2 as a risk gene for Intellectual Disability (ID),7 prompted us to re-evaluate the genomic information available for a large cohort of patients affected by ASD and/or ID who had previously been analysed by WES. This included our in-house cohort (2250 total samples, 736 affected) as well as a publicly available one from the ASC (35 584 total samples, 11 986 affected).11 No further likely pathogenic variants or variant of unknown significance in neurodevelopment-related genes2 were identified. A search in the DECIPHER database19 for novel TLK2 deletions was also performed. We found six cases in three independent families with detrimental variants in the TLK2 gene (figure 1A–F).

In family 1, the proband carried a de novo missense change c.1652A>G; p.(Asp551Gly) not reported in gnomAD and predicted to be damaging by multiple in silico predictors (online supplemental table S5). This variant localises in a highly Constrained Coding Region (CCCR) (>93th percentile) within the PKD.20 In family 2, three affected siblings carried a premature stop variant (c.1423G>T; p.(Glu475Ter)) inherited from their affected mother (case 2). This variant was not reported in gnomAD and was classified as pathogenic using the American College of Medical Genetics (ACMG) criteria.18 A sixth case (family 3) was identified in the DECIPHER database: a female carrying a likely pathogenic (class 4) de novo del(17)(q23.2), whose minimum size was 39 kb (chr17:60683462–60722398) identified in case 6 from family 3. The 39 kb deletion encompassed TLK2 and MRC2 genes. (G) Frontal and lateral face photographs of our cases, showing overlapping facial dysmorphism. Most frequently reported features were upward slanted palpebral fissures, broad nasal tip, thin lips, low hanging columella, prognathism, wide spaced eyes and downturned corners of the mouth. (H) Details of reported skeletal anomalies at the level of hands and feet. Upper left panel: tapered hands fingers from case 1; upper right panels: short hands with short distal phalanx from case 6; bottom left panel: postaxial polydactyly of left foot observed in case 3; bottom right panel: overriding second toe in case 4.

Figure 1  Facial features and skeletal anomalies of individuals with TLK2 variants. (A–C) Pedigrees of family 1, 2 and 3. Cases from family 1 and 3 carried respectively a heterozygous de novo missense variant (c.1652A>G; p.(Asp551Gly)) and a heterozygous de novo deletion encompassing TLK2 gene. Cases from family 2 shared a heterozygous premature stop variant (c.1423G>T; p.(Glu475Ter)) inherited from an affected mother. Analysis of maternal grandparent genotype were not possible, but familial clinical history did not suggest a possible MRD57-like phenotype for them. wt, wild type at variant position. (D–E) Sanger validation of variants identified in family 1 and 2. Validation was performed both on gDNA from affected cases and from their unaffected relatives. (F) 17q23.2 deletion (minimum size 39 kb, chr17:60683462-60722398) identified in case 6 from family 3. The 39 kb deletion encompassed TLK2 and MRC2 genes. (G) Frontal and lateral face photographs of our cases, showing overlapping facial dysmorphism. Most frequently reported features were upward slanted palpebral fissures, broad nasal tip, thin lips, low hanging columella, prognathism, wide spaced eyes and downturned corners of the mouth. (H) Details of reported skeletal anomalies at the level of hands and feet. Upper left panel: tapered hands fingers from case 1; upper right panels: short hands with short distal phalanx from case 6; bottom left panel: postaxial polydactyly of left foot observed in case 3; bottom right panel: overriding second toe in case 4.

it is unlikely that haploinsufficiency in MRC2 or MARCH10 contribute to the patient’s phenotype.

Our patients (three males and three females) ranged from 3 to 47 years of age, all of them were of Caucasian ethnicity. A broad range of behavioural disorders was present, including ASD (1/6), attention deficit hyperactivity disorder (4/6), anxiety (3/6), short attention span (2/6) and obsessive-compulsive behaviour (2/6). ID was reported for four patients in the borderline (IQ 70–85) or low (IQ ≤70) range. Patient 5 was too young for

Pavinato L, et al. J Med Genet 2020;0:1–10. doi:10.1136/jmedgenet-2020-107281
formal assessment of a neurodevelopmental phenotype, but a global developmental delay was reported. No formal evaluation for ID was provided for case 6 but difficulties in memory and transcription were reported. All affected members from family 2 had microcephaly. Dysmorphic facial features were observed in all patients and included upslanting palpebral fissures, wide nose, low hanging columella, smooth philtrum, prognathism, pointed chin and hypertelorism (figure 1G). Minor skeletal anomalies of the hands and feet were reported for four patients (figure 1H). Interestingly, some of the features we observed in a portion of our patients had not been described in previously reported cases, expanding the clinical phenotype. Among them, there were neurodevelopmental (difficulties in reading, writing, memory and transcription and pavor nocturnus), dysmorphic (prognathism, bifid nasal tip, low hanging columella, absent ear lobe, low-implant auricle, synophrys and downturned corners of mouth) and skeletal anomalies (postaxial polydactyly of left foot, overriding second toe, tapering fingers, short hands with short distal phalanges). A summary of the clinical phenotypes is reported in online supplemental table S6 and a description is provided in the online supplemental data, while a comparison with the available literature is provided in online supplemental table S7.

**TLK2 haploinsufficiency disrupts proper chromatin compaction**

Using qRT-PCR, we analysed TLK2 mRNA expression in LCLs from case 1 and fibroblasts from case 6. We found an approximately 50% reduction in TLK2 mRNA expression in both cases (figure 2A and online supplemental figure S1A). This was unexpected in case 1, who carried the c.1652A>G; p.(Asp551Gly) missense change. Variants encoding missense changes may induce unstable mRNA secondary structures leading to degradation of the altered allele.8 9 To verify if both alleles were expressed, we amplified and sequenced cDNA between exons 18 and 23. We found that both wild-type (WT) and mutant allele were present (online supplemental figure S1B), suggesting that the allele encoding the p.(Asp551Gly) variant was not degraded. Moreover, no differences were observed in band sizes from WT and p.(Asp551Gly) cDNAs (online supplemental figure S1C), excluding that p.(Asp551Gly) led to the production of aberrantly spliced transcripts.21 22 Western blot analysis on LCLs from case 1 compared with controls, uncovered a significant increase in TLK2 protein expression (online supplemental figure S1D), motivating us to perform a deeper characterisation of the impact of p.(Asp551Gly) on TLK2 activity.

Based on the role of TLK2 in controlling chromatin remodelling,2 we investigated possible changes in chromatin compaction, performing the SCGE assay with LCLs derived from case 1. Relatively short electrophoresis time was already sufficient to unmask slight differences between control and mutant cells. Longer run times allowed DNA loops to stretch under the electric field and revealed a significantly more relaxed state of nucleoids between LCLs carrying the p.(Asp551Gly) amino acid change and control cells after 20 min of electrophoresis run time (**p<0.05; two-tailed unpaired Student’s t-test with Welch’s correction), that became more evident after 60 min of electrophoresis run time (***p<0.0001; two-tailed unpaired Student’s t-test with Welch’s correction). DNA migration was quantified as Tail moment values, which is defined as the product between the tail length and the percentage of DNA in the tail. For each point, at least 100 cells were analysed. Values are represented as mean±SEM of three independent experiments. (C) Representative images of nucleoids derived from control LCLs and LCLs from affected subject 1 referred to experiment shown in (B). (D) Single and double strand breaks were induced by γ-ray irradiation (2 Gy or 4 Gy). Tail moment values specify the amount of γ-ray-induced DNA damage measured immediately after the treatment. The mutant LCLs showed a higher vulnerability to 2 Gy γ-ray irradiation (***p<0.0006; two-tailed unpaired Student’s t-test with Welch’s correction). Following 4 Gy treatment, no differences were observed between control and mutant cells, which is likely explained by the observation that the overall damage, especially double strand breaks, prevails on the condensation state of chromatin at high doses of γ-ray irradiation. For each point, at least 100 cells were analysed and four independent experiments were performed. (E) Representative images of nucleoids derived from control LCLs and LCLs from affected subject 1 referred to experiment shown in (D). ns, not significant.

**Figure 2** TLK2-Asp551Gly affects chromatin density and confers susceptibility to DNA damage. (A) TLK2 mRNA levels in fibroblasts from case 6 and in lymphoblastoid cell line derived from case 1. TLK2 expression was significantly reduced both in lymphoblastoid cell (LCL) carrying p.(Asp551Gly) variant and in fibroblasts carrying the 17q23.2 deletion. All experiments were performed at least in triplicate. UPL probe #72 and primers indicated in online supplemental materials and methods were used; HMBS mRNA expression was used as reference. Statistical analysis was performed using t-test with Welch’s correction; ***p≤0.0001. Numbers at the top of the bars indicated mean values. (B) Single-cell gel electrophoresis (SCGE) assays highlighted significant differences in chromatin condensation between LCLs carrying the p.(Asp551Gly) amino acid change and control cells after 20 min of electrophoresis run time (**p<0.05; two-tailed unpaired Student’s t-test with Welch’s correction), that became more evident after 60 min of electrophoresis run time (***p<0.0001; two-tailed unpaired Student’s t-test with Welch’s correction). DNA migration was quantified as Tail moment values, which is defined as the product between the tail length and the percentage of DNA in the tail. For each point, at least 100 cells were analysed. Values are represented as mean±SEM of three independent experiments. (C) Representative images of nucleoids derived from control LCLs and LCLs from affected subject 1 referred to experiment shown in (B). (D) Single and double strand breaks were induced by γ-ray irradiation (2 Gy or 4 Gy). Tail moment values specify the amount of γ-ray-induced DNA damage measured immediately after the treatment. The mutant LCLs showed a higher vulnerability to 2 Gy γ-ray irradiation (***p<0.0006; two-tailed unpaired Student’s t-test with Welch’s correction). Following 4 Gy treatment, no differences were observed between control and mutant cells, which is likely explained by the observation that the overall damage, especially double strand breaks, prevails on the condensation state of chromatin at high doses of γ-ray irradiation. For each point, at least 100 cells were analysed and four independent experiments were performed. (E) Representative images of nucleoids derived from control LCLs and LCLs from affected subject 1 referred to experiment shown in (D). ns, not significant.
deletion encompassing TLK2 (online supplemental figure S2), suggesting a similar effect between the 17q23.2 deletion and the p.(Asp551Gly) variant. Overall, these findings demonstrated that TLK2 haploinsufficiency disrupts proper chromatin organisation and confers susceptibility to DNA damage.

**TLK2 missense mutations alter the activity and subcellular localisation of the protein**

All of the TLK2 missense mutations in the PKD from MRD57 analysed to date exhibited decreased kinase activity, including H493R, H518R, R720A and D629N10 (online supplemental figure S4B). Given that the high conservation of the mutated residues in the PKD suggested reduced kinase activity, we examined the potential structural impact of the missense p.(Asp551Gly) (hereafter indicated as D551G) variant identified in our survey, as well as the p.(Ser617Leu) (hereafter indicated as S617L) variant, found in a patient with ASD already described in WES works.11–13 The patient was also reported in the ASC exome analysis browser, a freely accessible portal containing de novo variants identified in >6000 affected probands enrolled in ASC WES projects (https://asc.broadinstitute.org/). Residue S617 is located one residue after the Asp-Phe-Gly (DGF) motif,23 24 which together with the activation and catalytic loop, constitute the kinase core.10 We previously identified S617 as a TLK2 auto-phosphorylation site and demonstrated that alterations of this site are able to significantly enhance (S617A) or reduce (S617D) TLK2 kinase activity.10 Therefore, it remained an open question how S617L, associated with ASD, would influence the kinase activity of TLK2.

We modelled both of the mutations using the crystal structure of the TLK2 PKD.10 TLK2-D551G was predicted to weaken hydrogen bonds with the subsequent helix and S617L introduces a hydrophobic residue in place of the autophosphorylation site in the activation loop (figure 3A,B).

To determine if these mutations affected kinase activity, we analysed TLK2 activity using in vitro kinase assays. Ectopically expressed, Strep-FLAG tagged TLK2, TLK2-KD (kinase dead, D592V), TLK2-D551G and TLK2-S617L were affinity purified from AD-293 cells using an N-terminal Strep tag and incubated with purified substrate (ASF1A) for kinase assays. Both mutations led to a notable reduction in substrate modification (figure 3C,D). Quantification of multiple experiments demonstrated that TLK2-S617L severely impaired kinase activity, comparable to the TLK2-KD protein, while TLK2-D551G was more mildly impaired and showed slightly higher autophosphorylation levels than TLK2-WT in some experiments (figure 3D).

In previous work, we noted that loss of the coiled-coil domains of TLK2 led to perinuclear accumulation.10 To determine if the TLK2-D551G and TLK2-S617L missense mutations altered TLK2 localisation, we transfected FLAG-tagged mutants in AD-293 cells and performed immunofluorescence (IF) microscopy. Lamin A was used as an inner nuclear membrane marker and nuclear DNA was stained with DAPI. TLK2-WT showed diffuse nuclear localisation in transfected cells, as observed previously (figure 3E, online supplemental figure S3A). In contrast, TLK2-D551G and TLK2-S617L showed perinuclear localisation to different extents (figure 3E,F, online supplemental figure S2A). This was particularly prominent for the TLK2-S617L mutant, where 75% of transfected cells showed a perinuclear localisation of TLK2 (figure 3E,F).

The proximal interactome of TLK2 is altered by missense mutations

TLK2 is involved in many biological processes and few clear substrates aside from ASF1A and ASF1B have been well characterised.2 As kinases often bind to substrates with low affinity, we previously used an unbiased proximity biotinylation assay coupled to mass spectrometry (BioID-MS), as it does not require high-affinity interactions that can withstand purification procedures.2 25 We used this approach to further characterise the
cellular environment of TLK2 and determine if the missense mutations influenced its interactome.

BirA-tagged TLK2-WT, TLK2-D551G and TLK2-S617L were expressed in AD-293 cells by transient transfection (figure 4A). Network clustering of results from WT TLK2 (TLK2-WT) identified the known TLK2 substrates ASF1A, ASF1B and TLK1, as well as the DYNLL1/2 (LC8) proteins that we previously validated.5 10 The proximal interactome grouped into five functional clusters consistent with the known functions of TLK2, including RNA processing and splicing, transcriptional regulation, chromatin binding or remodelling, DNA repair and histone chaperones (figure 4B and online supplemental table S8). We cross-referenced the proximal interactome with a recent large-scale analysis of iPOND-MS data that identified TLK1 and TLK2 as high confidence interactors with nascent DNA at active replication forks.26 Several of the TLK2-WT hits, including RAD50, BRD4, CHD8, ASF1B, SCML2 and NACC1 were also found at active forks with high confidence in iPOND studies. We next compared our TLK2-WT proximal interactome with the Simon’s Foundation Autism Research Initiative (SFARI)/DECIPHER database and identified eight proteins: CHD7, CHD8, NACC1, CCNK, JMJD1C, RAD50, MSANTD2 and YEATS2. These data suggest potential functional links between TLK2 and a number of proteins involved in neurodevelopmental disorders with overlapping pathologies. Details about SFARI and OMIM classifications are provided in online supplemental table S9.
In parallel to TLK2-WT, we performed BioID analysis with TLK2-D551G and TLK2-S617L. Both mutants accumulated to higher levels than TLK2-WT, consistent with what we previously observed with other inactive TLK2 mutants. Both mutants caused numerous alterations in the proximal interactions compared with TLK2-WT (figures 4C,D and 5). This included a reduction in several replication fork and ASD-related proteins, including RAD50 and YEATS2 with both mutants, and JMJD1C, BRD4, CCNK, NACC1, MSANTD2 and CHD8 with TLK2-S617L (figures 4 and 5). In addition, some proteins, including ZNF148, NFIA, NFIX and PAPOLG, that are all in the SFARI database, were significantly enriched with both mutants, but not TLK2-WT. (figures 4C,D and 5)

The CHD7 and CHD8 chromodomains were of particular interest to us because they are mutated respectively in CHARGE syndrome (MIM# 214800) and susceptibility to autism (MIM# 615032) and implicated in modulating chromatin structure. In contrast, CHD8 spectra were detected at similar levels between TLK2-WT and TLK2-D551G, which retains some activity, but were reduced with the kinase dead TLK2-S617L (figures 4C,D and 5). In contrast, CHD7 spectra were highest in cells expressing TLK2-D551G. We performed BioID-Westerns to validate these proximal interactions and their relative differences. Expression of the control N-FLAG-BirA and biotin supplementation led to no detectable CHD7 or CHD8 detected in western blot analyses (figure 6). In contrast, both CHD7 and CHD8 were clearly validated with all TLK2 alleles, although CHD8 levels were lowest with S617L and CHD7 highest in TLK2-D551G, consistent with the MS data. As expected from the BioID-MS, TLK1 co-purified with all TLK2 alleles to a similar degree. It was also notable that the substrates, ASF1A and ASF1B, were highest with D551G and similar between TLK2-WT and TLK2-S617L, despite the much higher level of TLK2-S617L expression. These results indicate the missense mutations have differential effects on both proximal interactions and TLK-ASF1 interactions.

DISCUSSION

To our knowledge, at least 13 TLK2 missense variants have been reported in MRD57 cases, with mutations clustering in the PKD. Previously described patients showed ID in different range of severity, ASD, language delay, motor delay, gastrointestinal issues and dysmorphic facies as prevalent features. In our cases, we confirmed a high incidence of ID (4/4), language delay (4/6) and dysmorphic facial features (6/6). On the contrary, compared with the available clinical literature, we observed a
under-representation of gastrointestinal problems (0/6) and ASD (1/6). We also observed additional features, including difficulties in reading and writing (3/6) or in memory and transcription (3/6) and skeletal anomalies of the hands (1/6) and the feet (1/6).

Functional characterisation has been reported for only four variants in the PKD, (p.(His493Arg), p.(His518Arg), p.(Asp629Gln), p.(Arg720Ala)) and has shown at least a 50% reduction in enzymatic activity compared with WT protein. Our data further expands the characterisation of MRD57 missense mutations and reinforces the prevailing hypothesis that the majority of these impair TLK2 kinase activity. Both TLK2-D551G and TLK2-S617L showed profoundly impaired kinase activity, as well as altered subcellular localisation, the significance of which remains unclear (figure 3, online supplemental figures S3 and S4). As also suggested by in silico tools (online supplemental table S5), TLK2-S617L caused a more severe impairment of protein activity and localisation compared with TLK2-D551G mutant. It is interesting to note that case carrying p.(Asp617Leu) was characterised by a mild-to-severe ID, with a IQ (verbal IQ 63, non-verbal IQ 74) that was lower than the one observed in case carrying p.(Asp551Gly) variant and comparable to the one observed in patients carrying p.(Glu475Ter) variant (online supplemental table S6). Based on the limited available clinical information, we could therefore suggest that the higher impairment of the protein activity mediated by p.(Ser617Leu) variant could be reflected on the clinical side by a more severe phenotype.

Both mutants overexpressed in AD-293 cells showed higher expression compared with WT. Accordingly, LCLs carrying p.(Asp551Gly) variant showed significantly higher TLK2 protein levels compared with control. Surprisingly, the higher protein expression was counterbalanced by drastically reduced mRNA levels, suggesting a potential negative feedback control, further causing reduced TLK2 total mRNA levels.

Despite the severe effects on kinase activity caused by the heterozygous missense mutations identified in MRD57 patients to date, monoallelic Tlk2 loss did not cause overt phenotypes in mice, but neurodevelopment and behaviour were not assessed in these animals. Given that TLK2 dimerises with both TLK1 and TLK2 and this is important for its activity, it is also likely that kinase impaired mutants exert some dominant negative effects that contribute to an overall phenotype that is more severe than haploinsufficiency. The recent identification of multiple MRD57 cases with TLK2 haploinsufficiency suggests that an in-depth evaluation of neurodevelopment is needed in mice with reduced TLK2 levels to determine if they represent a model of MRD57. The placental issues observed in mice with homozygous deletion of Tlk2 were not identified in Tlk2 heterozygous mice, but human gestation is considerably longer, and more subtle placental issues could be present. Recent work showed that total TLK depletion leads to an innate immune secretory response in cancer cells and mice. Maternal immune activation has been implicated in ASD and associated with placental defects in mice, suggesting that impaired chromatin maintenance and epigenetic dysregulation could potentially underlie the pathological effects of TLK2 haploinsufficiency. This is consistent with the increased chromatin accessibility reported here in TLK2-D551G patient cells (figure 2B–E), as well as the strong enrichment of chromatin proteins in the TLK2 interactome in the SFARI and DECIPHER databases.

Many genes encoding proteins involved in chromatin remodelling are associated with neurodevelopmental disorders. TLK2, as well as the missense mutants we tested, showed proximal interactions with many of them, including CHD8 and CHD7, that are mutated in ASD and CHARGE syndrome. In addition to these proteins, both TLK2 missense mutants showed altered interactions with additional proteins implicated in neurodevelopment. This included RAD50, a part of the MRE11-RAD50-NBS1 DNA repair complex that localises to replication forks and plays a key role in DNA-double-strand break repair. RAD50 mutations, present in the DECIPHER database, underlie Nijmegen breakage syndrome-like disorder (MIM# 613078). This condition is characterised by microcephaly, which is also commonly observed in many patients with TLK2 variants. Furthermore, RAD50 proximal interactions were reduced with both missense mutants, potentially suggesting reduced localisation to replication forks (figure 5). Similarly, YEAT2S, a chromatin reader component, is suggested as an ASD-associated gene by de novo genetic risk analysis and GWAS (SFARI database criteria 3.1, suggestive evidence), was linked to epilepsy and was enriched with TLK2-WT compared with either missense mutant. In contrast, ZNF148 and PAPOLG, that are also associated with neurodevelopmental disorders, were strongly enriched with both missense mutants and detected at very low levels with TLK2-WT, while other SFARI genes, including BRD4, JMJ1D1C, MSANTD2, CCNK and NACC1 were reduced specifically with the less active TLK2-S617L variant. In future work, it will be of interest to examine the potential functional relevance of these interactions to determine if their alterations underlie the altered chromatin state we observed in LCLs from case 1 or other phenotypes associated with TLK2 loss of function. This approach may detect new candidate genes involved in neurodevelopmental disorders or help us understand the involvement of this network of SFARI genes in isolated or syndromic ASD and ID.

The knowledge of altered protein interactomes is important to understand the molecular impact of disease mutations and could be helpful in identifying pharmacological treatments to mitigate more severe phenotypes, such as epileptic seizures. It is attractive to imagine the possibility of repurposing drugs able to modulate the functions of some genes to influence their impact on disease pathology.

In conclusion, we provided the clinical description of six new cases carrying likely pathogenic and pathogenic TLK2 variants and we presented new insights into the impact of TLK2 missense variants, observing impairment in kinase activity, localisation and interaction (online supplemental figure S4). Our work offers a deep characterisation of two missense variants localised in a key domain of the TLK2 protein, where most mutations related to MRD57 disorder occur, providing new insights into the potential role TLK2 in neurodevelopmental disorders.

Author affiliations
1Department of Medical Sciences, University of Turin, Torino, Italy
2Institute of Human Genetics and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
3The Barcelona Institute of Science and Technology, Institute for Research in Biomedicine, Barcelona, Spain
4Department of Environment and Health, Istituto Superiore di Sanità, Roma, Italy
5Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy
6Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
7Medical Genetics Unity, Sant’Orsola-Malpighi University Hospital, Bologna, Italy
8Department of Pediatrics and Public Health and Pediatric Sciences, University of Turin, Torino, Italy
9Department of Molecular Medicine, University of Pavia, Pavia, Italy
10Department of Sciences for Health Promotion and Mother and Child Care “G. D’Alessandro”, University of Palermo, Palermo, Italy
11Department of Genetics, Reference center for Rare Diseases and Developmental Anomalies, Caen, France
Twitter Lisa Pavinato @lisapavinato

Acknowledgements The authors would like to thank the patients and their families for their precious collaboration.

Contributors MV-P, MSC, MG, MV and GA-G performed activity, localisation and BiO-ID analysis. LP wrote and edited the manuscript, interpreted exome data, collected the cases and performed variant confirmation, mRNA and splicing analysis. CA and VP performed the SCGE assay. EG interpreted exome data. DC, VRAMO, KK and CC followed patients and collected their clinical information. SDR and JP performed exome sequencing. AB, TP, PD, AC, FCR and MT processed and analysed the WES data. THS and AB designed and supervised the project, analyzed data and wrote the manuscript.

Funding This research received funding specifically appointed to Department of Medical Sciences from the Italian Ministry for Education, University and Research (Ministero dell’Istruzione, dell’Università e della Ricerca—MIUR) under the programme ‘Dipartimenti di Eccellenza 2018–2022’ Project code D15D18000410001. MV-P was funded by an EPI fellowship from the Ministry of Science, Innovation and Universities (MCIU) and MSC by a Masters fellowship from the BIST and support from the IRB Barcelona. THS was funded by the MCIU (PIG2018-095616-B-I00/GINDATA and FEDER). MT was funded by Fondazione Bambino Gesù (Vite Coraggiose). The whole exome sequencing was performed as part of the Autism Sequencing Consortium and was supported by the NIMH (MH111661). Thanks to the MSPTC of IRB Barcelona, a principal unit in Proteomed, PRBS, supported by PIT1/2019 of the PE I+D+i 2013–2016, funded by SII and ERDF. This study makes use of data generated by the DECIPHER community. A full list of centres that contributed to the generation of the data is available from: http://decipher.sanger.ac.uk and via email from: decipher@sanger.ac.uk. Funding for the project was provided by the Wellcome Trust.

Competing interests None declared.

Patient consent for publication Parental/Guardian consent obtained.

Ethics approval The study protocol was approved by the internal Ethics Committee, according to the Declaration of Helsinki and informed consent was obtained from participating families.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository or included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs
Lisa Pavinato http://orcid.org/0000-0002-7630-8365
Marina Villamor-Payà http://orcid.org/0000-0002-7288-4197
Alessandro Brusco http://orcid.org/0000-0002-5951-4998
Elisa Giorgia http://orcid.org/0000-0003-4076-4649
Francesca Clementina Radio http://orcid.org/0000-0003-1993-8018
Kara Ragoon http://orcid.org/0000-0002-9732-8090
Travis H Stracker http://orcid.org/0000-0002-6850-2081

REFERENCES

1 Lee SB, Segura-Bayona S, Villamor-Payà M, Saredi G, Todd MAM, Attolini CS-O, Chang T-Y, Stracker TH, Groth A. Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors. Sci Adv 2018;4.

2 Segura-Bayona S, Stracker TH. The Tousled-like kinases regulate genome and epigenome stability; implications in development and disease. Cell Mol Life Sci 2019;76:3827–41.

3 Bruinsma W, van den Berg J, Aprelia M, Medema RH. Tousled-like kinase 2 regulates recovery from a DNA damage-induced G2 arrest. EMBO Rep 2016;17:659–70.

4 Klimovskaia IM, Young C, Strømme CB, Menard P, Jasencakova Z, Mejlvang J, Ask K, Rølolde K, Nugent GM, Cremer K, Strom TM, Bird LM, Sinnema M, Blither-Gliindzicz M, van Maastricht M, Alders M, Kosman A, Brick L, Kocezak K, Harline ML, Klassems M, Steinraths M, Cooper NS, Edery Y, Pap P, Terhal PA, van der Pijl P, Lakeman P, Taylor RL, Plout HR, Mercimek-Arends S, Stegmann APA, Kant SG, McLean S, Joss S, Swagemakers SMA, Dougozou S, Wall SA, Kuiy S, Calipena E, Koelling KM, McGowan SJ, Twigg SR, Mathijssen IMJ, Nellaker C, Brunner HG, Willkomm AO, Novo D, Deciphering Developmental Disorders Study. De novo and inherited loss-of-function variants in TLK2: clinical and genotype-phenotype evaluation of a distinct neurodevelopmental disorder. Am J Hum Genet 2018;102:1195–203.

5 Töpf A, Oktay V, Balaraju S, Yilmaz E, Sonmezte E, Yis U, Laurie S, Thompson R, Roos A, MacArthur DG, Yaramis A, Göngür S, Lochmüller H, Hös C, Horvath R. Severe neurodevelopmental disease caused by a homologous TLK2 variant. Eur J Hum Genet 2019.

6 Leivelied SH, Reinders MRF, Pihlstr R, Yntema HG, Kamsteeg E-J, van Dijl P, de Vries BBA, Willemse MH, Kleefstra T, Linnert K, Vreeburg M, Stevens VC, van der Burgt I, Bongers EMHF, Stegmann APA, Rump P, Rinne T, Nelsen MR, Veltman JA, Vissers LELM, Brunner HG, Gilsen C. Meta-Analysis of 2,104 trios provides support for 10 new genotypes for intellectual disability. Nat Neurosci 2019;11:1949–64.

7 Mortaza GA, Hermita D, Pedersen A-K, Segura-Bayona S, López-Méndez B, Redondo P, Rüther P, Pozdnyakov I. Garrote AMM, Muñoz IG, Villamor-Payà M, Jassett C, Olsen JV, Stracker TH, Motanya G. Molecular basis of Tousled-like kinase 2 activation. Nat Commun 2019;3:2553.

8 Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubis S, An J-Y, Peng M, Collins R, Grove J, Klei L, Stevens C, Reichert J, Melum MS, Artomov M, Géres G, Sheppard B, Xu X, Bhaduri A, Norman U, Brand H, Schatz M, Nguyen R, Guerrero EE, Dias C, Betancur C, Cook EH, Gallagher L, Gill M, Sutcliffe JS, Thumb A, Zwick ME, Bargum AD, State MW, Cikic AE, Taowatke MS, Cifuni D, Devlin B, Sanders SJ, Roeder K, Daly MJ, Buxbaum JD, Alexsis B, Arney R, Barbosa M, Bishop S, Brusco A, Bybjerg-Graihoul J, Carrazione A, Chan MC, Chiochetti AG, Chung BHY, Coon H, Cuccaro ML, Curro A, Dalla Bernardina B, Doan R, Domeniuss E, Dong S, Fallerini C, Fernández-Prieto M, Ferreiro GB, Freitag CM, Fromer M, Gargus JJ, Geschwind D, Geigio D, González- Peñas J, Guter S, Halpren D, Hanssen-K E, He X, Herman GE, Hertz-Picottco I, Hoogdu GD, Hultman CM, Imonia-Laiza J, Jacob S, Jamison J, Jugessur A, Kaartonien M, Knudsen GP, Kolevzon A, Lea SL, Steinhart LM, Tim LT, Lintas C, Lipkin W, Lopergolo D, Lopes F, Judena Y, Maciel P, Magnus P, Mahjani B, Maltman N, Manoach DS, Meigl M, Menache I, Miller J, Minshew N, Montenegro EMS, Moreira D, Morrow EM, Mors O, Mortensen PB, Mosconi M, Peale PG, Nadeau BE, Nordentoft M, Ozaiki N, Polatia E, Parellada M, Passos-Bueno MR, Pericak-Vance M, Persico AM, Pessah I, Pichauro K, Reichenberg A, Renieri A, Ribeiro E, Robinson EB, Samocha KE, Sandin S, Santangelo SL, Schellenberg G, Scherer SW, Schmidt M, Schluth-Bolard C, Deshpande K, Seidman J, Sipker P, Susser E, Sweeney J, Szatmari P, Tang L, Tassone F, Teufel K, Trabetti E, Autism Sequencing Consortium, iPSYCH-Broad Consortium. Large-Scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 2020;180:568–84. doi:10.1016/j.cell.2019.12.036

9 Jossifov O, L’Rooat BJ, Sanders SJ, Ronenius M, Krumn Y, Levy D, Stessman HA, Wijerspoon KT, Vives L, Patterson KE, Smith JD, Paober B, Nickerson DA, Dea J, Dong S, Gonzalez LE, Mandell A, Mane SM, Murtha MT, Sullivan CA, Walker MW, Warner Z, Andrews P, Petta A, Kendall J, Hakker I, Rosenbaum JA, B, Rodgers L, Troge J, Narziss G, Yoon S, Schacht M, Ye K, McCombie WR, Shendure J, Eicher EE, State MW,
Cognitive and behavioural genetics contribute to autism spectrum disorder.

Nature 2014;515:251–16.

10 O’Roak BJ, Derkitsis P, Lee C, Vives L, Schwartz JJ, Girirajan S, Karakoc E, Mackenzie AP, Ng SB, Baker K, Rieder M, Nickerson DA, Bernier R, Fisher SE, Shendure J, Eichler EE. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 2011;43:509–515.

14 De Rabouillet S, He X, Goldberg AP, Poultney CS, Samocha K, Cicak A, Koyu Y, Liu L, Fromer M, Walker S, Singh T, Klei L, Kosmicki J, Shi-Hen Chen F, Aleksic B, Biscaldi M, Bolton PF, Brownfield JM, Cai J, Campbell NG, Carracedo A, Chauroir MH, Chiocchetti AG, Coon H, Crawford EL, Curran SR, Dawson G, Dukites E, Fernandez BA, Gallagher L, Geller E, Gutter SJ, Hill RS, Ionita-Laza I, Jimenez Gonzalez P, Klippen H, Klauck SM, Kolevzon A, Lee J, Lee J, Lei J, Leshkowitz T, Lin CF, Ma’ayan A, Marshall CR, Mccinnes AL, Neale B, Owen MJ, Ozaki N, Parella M, Parvin J, Parvizar S, Persico S, Piraci K, Rajagopalan D, Reinstein K, Reichenberg A, Sabo A, Sachsce M, Sanders SJ, Schafer C, Schultz-Ruther M, Skuce D, Stevens C, Szatmari P, Tamburro M, Valladares O, Voran A, Li San W, Weiss LA, Wissely AJ, Yu TW, Yuan RKC, Cook EH, Freitag CM, Gill M, Hultman CM, Lehrer T, Palote A, Schellenberg GD, Sklar P, State M, Wiltshire JS, Walsh AC, Scherer SW, Zwick ME, Barett JC, Cifteri D, Roeder K, Devlin B, Daly MJ, Buxbaum JD, IDD Study. Homozygosity Mapping Collaborative for Autism, UK10K Consortium. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014;520:205–19. doi:10.1038/nnature13772

15 Kupans C, Tsiloskos V, Koursi A, Chapple CE, Albacara Aguila M, Meyer R, Massouras A, VarSome: the human genomic variant search engine. Bioinformatics 2019;35:1978–80.

16 Desmet F-O, Hamroun D, Lalande M, Collod-Béroud G, Clastres M, Beroud C. Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009;37:262–7.

17 Exe I, Martellini L, Van Dijck A, Cioffi G, Cecchetti S, Coluzzi E, Pannone L, Andreoli A, Vijayan RSK, He P, Modi V, Duong- Ly KC, Ma H, Peterson JR, Dunbrack RL, Levy RM. Siwaszek A, Ukleja M, Dziembowski A. Proteins involved in the degradation of yeast Mdm2, a negative regulator of p53. EMBO J 2014;33:2807–2818.

18 Manning KS, Cooper TA. The roles of RNA processing in translating genotype to phenotype in humans using Ensembl resources. Nat Genet 2009;41:15–20.

19 Roux KJ, Kim DI, Burke B, May DG. BioID: a screen for protein-protein interactions. Nat Biotechnol 2004;22:44–50.

20 Lalani SR, Safiullah AM, Fernbach SD, Harutyunyan KG, Thaller C, Peterson LE, Res splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2017;45:745–6.

21 Manning KS, Cooper TA. The roles of RNA processing in translating genotype to phenotype in humans using Ensembl resources. Nat Genet 2009;41:15–20.

22 Ruzzo EK, Pérez-Cano L, Jung J-Y, Wang L-K, Hashig-Mahgbi H, Hart C, Singh C, Xu J, Hoekstra JN, Leventhal O, Leppä VM, Ganal MJ, Paskov K, Stockman N, Poliadikus D, Lowe JK, Prober DA, Geschwind DH, Wall DP. Inferred and de novo genetic risk for autism impacts shared networks. Cell 2019;178:850–66.

23 Arney R, Keri L, Pintz D, Almeida J, Barcia E, Baier G, Bolshakova N, Bilte S, Bolton PB, Bourgeot B, Tenen S, Brian S, Brij J, Casey L, Conroy J, Correia C, Corsello C, Crawford EL, de Jonge M, Delarze M, Dukites E, Duque E, Estilhés A, Farrar P, Fernandez BA, Folstein SF, Embonneur B, Gillette J, Gilberg C, Glessner JT, Green A, Green J, Guter SJ, Heron EA, Holt R, Howe J, Hughes G, Huis V, Iglziczi R, Jacobs S, Kenny GP, Kim C, Kolevzon A, Kustovnich LJ, Lancome CB, Lamba MJ, Law-Smith M, Leboyer M, Le Couteur A, Leventhal BL, Liu X-Q, Lombard F, Lord C, Lopudessi L, Lund SC, Magalhaes TR, Mantoulou C, McDougall CJ, Melkhim NM, Merkangas AM, Minakh NM, Milica G, Monus J, Nefas C, Nygren G, Papanikloaou K, Pagonatma MT, Parin J, Paton B, Tickle F, Pileks P, Dousabhoy G, Li Y, Williams B, De Benedetti A. A dominant negative mutant of CHD7 reduces CHD8 levels in developing neurons. Hum Mol Genet 2019;28:1382–93.

24 Silva J, Alivo S, Knebel PA, Bailey IL, Casilli A, Vinaixa M, Garcia-Caro I, Croyaud Etienne, Jurdain AA, Pérez-Ferreros P, Rojas AM, Antinop-Loines-Tall Fontaine S, Samino-Gómez S, Raught B, Gonzalez-Reyes A, Ribas de Pouplana L, Doherty AJ, Yanes O, Stracker TH. TaqMan® assay for selective histone crotonylation reader. Nature 2014;515:209–15.

25 Arney R, Keri L, Pintz D, Almeida J, Barcia E, Baier G, Bolshakova N, Bilte S, Bolton PB, Bourgeot B, Tenen S, Brian S, Brij J, Casey L, Conroy J, Correia C, Corsello C, Crawford EL, de Jonge M, Delarze M, Dukites E, Duque E, Estilhés A, Farrar P, Fernandez BA, Folstein SF, Embonneur B, Gillette J, Gilberg C, Glessner JT, Green A, Green J, Guter SJ, Heron EA, Holt R, Howe J, Hughes G, Huis V, Iglziczi R, Jacobs S, Kenny GP, Kim C, Kolevzon A, Kustovnich LJ, Lancome CB, Lamba MJ, Law-Smith M, Leboyer M, Le Couteur A, Leventhal BL, Liu X-Q, Lombard F, Lord C, Lopudessi L, Lund SC, Magalhaes TR, Mantoulou C, McDougall CJ, Melkhim NM, Merkangas AM, Minakh NM, Milica G, Monus J, Nefas C, Nygren G, Papanikloaou K, Pagonatma MT, Parin J, Paton B, Tickle F, Pileks P, Dousabhoy G, Li Y, Williams B, De Benedetti A. A dominant negative mutant of CHD7 reduces CHD8 levels in developing neurons. Hum Mol Genet 2019;28:1382–93.